Innate Pharma (IPHYF) Assets (2017 - 2025)

Innate Pharma's Assets history spans 9 years, with the latest figure at $73.0 million for Q4 2025.

  • For Q4 2025, Assets fell 38.48% year-over-year to $73.0 million; the TTM value through Dec 2025 reached $583.5 million, down 28.54%, while the annual FY2025 figure was $73.0 million, 39.26% down from the prior year.
  • Assets reached $73.0 million in Q4 2025 per IPHYF's latest filing, down from $118.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $306.0 million in Q4 2021 to a low of $73.0 million in Q4 2025.
  • Average Assets over 5 years is $177.9 million, with a median of $188.5 million recorded in 2023.
  • Peak YoY movement for Assets: decreased 7.3% in 2023, then plummeted 38.48% in 2025.
  • A 5-year view of Assets shows it stood at $306.0 million in 2021, then tumbled by 33.55% to $203.3 million in 2022, then decreased by 7.3% to $188.5 million in 2023, then plummeted by 37.04% to $118.7 million in 2024, then tumbled by 38.48% to $73.0 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Assets are $73.0 million (Q4 2025), $118.7 million (Q4 2024), and $188.5 million (Q4 2023).